Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of the combination of chloroquine with azithromycin and interferon beta-1b for the treatment of COVID-19

Next Previous
Trial Profile

A clinical trial of the combination of chloroquine with azithromycin and interferon beta-1b for the treatment of COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary) ; Chloroquine (Primary) ; Interferon beta-1b (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Bayer

Most Recent Events

  • 24 Apr 2020 New trial record
  • 21 Apr 2020 According to a Bayer media release, the Population Health Research Institute (PHRI) plans to enroll around 6000 subjects in the 2 trials, including this trial, assessing the combination of Bayer's chloroquine (Resochin) and interferon beta-1b (Betaferon), for the treatment of COVID-2019 infections.
  • 21 Apr 2020 According to a Bayer media release, the company has signed a collaborative partnership with the Population Health Research Institute (PHRI) for the conduction of an extensive clinical research programme, that will explore combination therapies of Bayer's chloroquine (Resochin) and interferon beta-1b (Betaferon), for the treatment of COVID-2019 infections in 2 clinical trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top